ISG15 silencing increases cisplatin resistance via activating p53-mediated cell DNA repair
Metrics: PDF 852 views | HTML 2038 views | ?
Yi Huo1,*, Zhaoyun Zong1,*, Qingtao Wang2, Zhenyu Zhang2 and Haiteng Deng1
1MOE Key Laboratory of Bioinformatics, School of Life Sciences, Tsinghua University, Beijing, China
2Beijing Chaoyang Hospital Affiliated to Capital Medical University, Beijing, China
Haiteng Deng, email: firstname.lastname@example.org
Keywords: cancer cells; drug-resistance; proteomics; ISG15; cisplatin
Received: June 23, 2017 Accepted: October 28, 2017 Published: November 18, 2017
Tumor cells frequently evolved resistance to cisplatin that greatly compromises the efficacy of chemotherapy. Identification of the mechanisms underlying drug resistance is important for developing new therapeutic approaches. ISG15 is found to be elevated in many human carcinomas and cancer cell lines. Here, we identified that the expressions of ISG15 and ISG15-conjugating system were downregulated in drug resistant A549/DDP cells compared to drug sensitive A549 cells. Silencing of ISG15 robustly elevated the resistance to cisplatin, suggesting ISG15 plays an important role in cisplatin resistance. Quantitative proteomics identified 1296 differentially expressed proteins between the control and ISG15 knockdown cells, showing that ISG15 silencing upregulated proteins in p53 pathway, adherens junction and nucleotide excision repair (NER) pathway. We also found that ISG15 silencing induced cell cycle arrest through stabilizing p53 and increasing HnRNP K expression, which allowed the prolonged time for cells to repair cisplatin-damaged DNA. Taken together, we proved that ISG15 downregulation activated the DNA damage/repair pathway to enhance cisplatin resistance in tumor cells.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.